AstraZeneca plc (AZN) Ordinary US$0.25

- Add to watchlist
- Create an alert
- This stock can be held in a




Share news, reports & tips
-
AstraZeneca spending $2.5bn on new R&D centre, biotech deals in China
21 March 2025 11:17
(Sharecast News) - Pharma giant AstraZeneca announced on Friday that it is investing $2.5bn in a new global R&D centre in China, along with major research and manufacturing agreements with three of the...
-
AstraZeneca buys biotech firm Esobiotec for up to $1bn
17 March 2025 07:21
(Sharecast News) - AstraZeneca announced on Monday that it is spending up to $1bn to acquire Belgian biotech firm EsoBiotec, which it says has the potential to "transform" cell therapy.
-
AstraZeneca hails trial results for imfinzi on gastric cancer
7 March 2025 07:03
(Sharecast News) - AstraZeneca said its Imfinzi drug when used with chemotherapy had shown "statistically significant and clinically meaningful improvement" in survival in resectable early-stage...
-
AstraZeneca's Imfinzi gets recommended for fresh EU approval
3 March 2025 07:26
(Sharecast News) - AstraZeneca announced on Monday that Imfinzi, or durvalumab, has been recommended for approval in the European Union for adults with resectable non-small cell lung cancer (NSCLC) at high...
-
AstraZeneca's camizestrant shows promise in breast cancer trial
26 February 2025 08:07
(Sharecast News) - AstraZeneca announced on Wednesday that its drug candidate camizestrant demonstrated a statistically significant and clinically meaningful improvement in progression-free survival in the...
-
London close: Stocks slip as US jobless claims rise
20 February 2025 16:06
(Sharecast News) - London equities ended lower on Thursday as investors reacted to a higher-than-expected rise in US jobless claims and a decline in UK consumer confidence.
-
UBS ups rating on AstraZeneca to 'buy'
13 February 2025 11:18
(Sharecast News) - UBS has upgraded AstraZeneca to a 'buy', citing the London-listed pharmaceutical firm's "sector-leading" drug pipeline.
-
Morgan Stanley sees huge upside at AstraZeneca
12 February 2025 10:21
(Sharecast News) - Morgan Stanley has initiated coverage of pharma giant AstraZeneca with an 'overweight' rating, recommending investors to build positions at a "compelling entry point".
-
Revenues, profits surge at AstraZeneca
6 February 2025 08:00
(Sharecast News) - AstraZeneca posted forecast-beating numbers on Thursday, fuelled by strong demand for its cancer and cardiometabolic drugs.
-
AstraZeneca's Imfinzi set for go-ahead by EU to treat lung cancer
3 February 2025 07:02
(Sharecast News) - AstraZeneca's Imfinzi has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adults with limited-stage small cell lung cancer (LS-SCLC)...
-
AstraZeneca's Enhertu gets new US approval
28 January 2025 07:03
(Sharecast News) - AstraZeneca and Daiichi Sankyo's Enhertu has been approved in the US for the treatment of adults with HER2 breast cancer, after disease progression having had one or more hormone...
-
AstraZeneca gets first US approval for cancer treatment Datroway
20 January 2025 07:30
(Sharecast News) - AstraZeneca announced on Monday that it has secured approval from the US Food and Drug Administration, alongside Daiichi Sankyo, for 'Datroway', or datopotamab deruxtecan, a...
Company announcements Announcements
-
AZN invests $2.5bn in Beijing R&D & manufacturing
21 March 2025 10:58
AstraZeneca
-
Eneboparatide Phase III trial met primary endpoint
17 March 2025 07:10
AstraZeneca
-
Imfinzi approved in EU for limited-stage SCLC
17 March 2025 07:05
AstraZeneca
-
AstraZeneca to acquire EsoBiotec
17 March 2025 07:00
AstraZeneca
-
Director/PDMR Shareholding
7 March 2025 15:00
AstraZeneca
-
Notice of AGM
7 March 2025 11:00
AstraZeneca
-
Imfinzi improved EFS in early-stage gastric cancer
7 March 2025 07:00
AstraZeneca
-
Director/PDMR Shareholding
6 March 2025 15:00
AstraZeneca
-
Director/PDMR Shareholding
5 March 2025 15:00
AstraZeneca
-
Total Voting Rights
3 March 2025 15:00
AstraZeneca
-
Imfinzi recommended for EU approval for AEGEAN
3 March 2025 07:00
AstraZeneca
-
Enhertu recommended in EU in post-ET breast cancer
28 February 2025 13:00
AstraZeneca
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2025. All rights reserved.
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.